PI3K inhibitors contribute to hepatic glycogenolysis and reduced glucose disposal into adipose tissue, leading to greater secretion of insulin from the pancreas and hyperinsulinemia (123, 142). The gene discussed is INS; the disease is hyperinsulinism.